MBOT MBOT
Company Profile ↓Company Overview
MBOT (MBOT) is a publicly traded company listed on . The valuation, growth and price-trend signals below summarize what matters most to investors and traders evaluating the stock.
Recent Developments
- Trailing 12 Months Year-on-year growth — revenue -88.4%.
- 5-Year Trend Long-term compounding — revenue CAGR -30.0%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | -29.99% |
| 1 Year: | -88.45% |
Stock Price Performance
| 1 Year: | -30.19% |
| 6 Months: | +2.78% |
| 3 Months: | -11.90% |
| 1 Month: | -2.63% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMABelow
- RSI (14)55.37 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
No notable strengths flagged.
CONS
- Revenue declined at -30.0% CAGR over 5 years.
- Trading 58.9% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Jun 2013 | Sep 2013 | Dec 2013 | Mar 2014 | Jun 2014 | Sep 2014 | Mar 2015 | Jun 2015 | Sep 2015 | Mar 2016 | Jun 2016 | Sep 2016 | Mar 2017 | Jun 2017 | Sep 2017 | Mar 2018 | Jun 2018 | Sep 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 105.00K |
| Gross Profit | 204.12K | 239.05K | - | 252.20K | 164.11K | 211.50K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 2.00K |
| Operating Income | -6.22M | -6.66M | - | -6.84M | -7.96M | -6.38M | -8.96M | -9.27M | -9.99M | 285.00K | 118.00K | -645.00K | -1.23M | -1.26M | -1.24M | -1.51M | -1.89M | -1.75M | -1.92M | -1.54M | -1.79M | -2.16M | -1.88M | -2.42M | -2.39M | -2.48M | -2.55M | -3.18M | -3.56M | -3.47M | -2.92M | -2.32M | -2.54M | -2.38M | -2.51M | -3.30M | -3.02M | -3.72M | -3.86M | -4.32M |
| Net Income | -5.87M | -7.19M | -6.96M | -7.62M | -12.12M | -2.76M | -9.35M | -8.46M | -9.64M | -276.00K | -164.00K | -652.00K | -1.31M | -3.51M | -1.19M | -1.48M | -1.89M | -1.76M | -1.96M | -1.54M | -1.87M | -2.21M | -1.85M | -2.47M | -2.39M | -2.51M | -2.56M | -3.19M | -3.51M | -3.47M | -2.85M | -2.29M | -2.45M | -2.37M | -2.46M | -3.21M | -2.60M | -3.50M | -3.58M | -3.67M |
| Diluted EPS | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -0.49 | -0.49 | -0.36 | -0.25 | -0.21 | -0.17 | -0.17 | -0.20 | -0.08 | -0.10 | -0.07 | -0.05 |
| R&D Expense | 4.80M | 5.18M | - | 4.63M | 5.84M | 4.40M | 6.29M | 7.24M | 7.72M | -219.00K | -44.00K | -340.00K | 184.00K | 377.00K | 339.00K | 496.00K | 747.00K | 623.00K | 587.00K | 741.00K | 843.00K | 691.00K | 669.00K | 1.04M | 1.12M | 1.39M | 1.39M | 1.71M | 2.19M | 1.95M | 1.62M | 1.36M | 1.61M | 1.17M | 1.42M | 2.06M | 1.46M | 2.11M | 1.17M | 1.29M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Nov 2014 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 992.87K | 1.43M | 1.22M | 1.37M | 172.30K | 1.01M | - | 116.89K | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | 731.43K | 1.26M | 1.01M | 1.10M | 886.64K | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Income | -29.38M | -29.36M | -28.08M | -21.91M | -28.09M | -30.91M | -30.91M | 915.00K | -9.63M | 5.27M | -7.24M | -7.24M | -9.09M | -11.36M | -13.28M | -9.86M | -11.62M | -14.74M |
| Net Income | -27.03M | -25.24M | -21.33M | -28.49M | -26.44M | -32.74M | -32.74M | -921.00K | -9.66M | -7.59M | -7.26M | -7.25M | -9.17M | -11.31M | -13.17M | -10.74M | -11.44M | -13.14M |
| Diluted EPS | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -1.81 | -1.05 | -0.73 | -0.29 |
| R&D Expense | 19.93M | 21.02M | 19.94M | 14.68M | 19.37M | 21.50M | 21.50M | -823.00K | -901.00K | 1.10M | 2.52M | 3.05M | 3.40M | 6.15M | 7.74M | 5.72M | 6.63M | 6.28M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2008 | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | - | 30.60M | 25.21M | 30.17M | 41.56M | 32.43M | 529.00K | 3.37M | 11.02M | 6.09M | 37.13M | 26.28M | 16.77M | 9.54M | 8.33M | 6.03M | 81.54M |
| Total Equity | 21.81M | 30.50M | 15.48M | 10.73M | 13.98M | 14.95M | 857.00K | -64.00K | 1.70M | 9.99M | 1.33M | 31.54M | 24.31M | 14.38M | 7.29M | 4.50M | 3.53M | 77.55M |
| Cash & Equivalents | 30.04M | 38.62M | 19.71M | 13.31M | 8.47M | 30.59M | 791.00K | 437.00K | 2.71M | 10.79M | 5.24M | 28.77M | 19.65M | 13.49M | 2.44M | 2.47M | 3.11M | 3.91M |
| Long Term Debt | - | - | 522.50K | 331.25K | 125.00K | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Total Liabilities | - | - | 15.12M | 14.48M | 16.19M | 26.60M | 26.56M | 419.00K | 1.17M | 556.00K | 4.76M | 5.59M | 1.97M | 2.39M | 2.25M | 3.83M | 2.50M | 3.99M |
| Current Liabilities | - | - | 5.53M | 5.65M | 5.10M | 9.13M | 11.50M | 174.00K | 783.00K | 528.00K | 4.76M | 4.83M | 1.34M | 1.98M | 2.07M | 3.79M | 2.46M | 3.42M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -24.68M | -24.52M | -22.06M | -19.87M | -23.32M | -27.35M | -765.00K | -786.00K | -4.86M | -5.31M | -6.45M | -7.25M | -9.35M | -11.55M | -8.53M | -8.83M | -13.05M |
| Investing Cash Flow | 3.73M | -923.96K | -3.42M | -10.69M | 9.04M | -425.62K | -2.00K | -25.00K | -58.00K | -223.00K | -2.45M | -2.77M | 3.20M | -3.84M | 1.97M | 1.54M | -72.38M |
| Financing Cash Flow | 29.79M | 6.59M | 19.13M | 25.74M | 36.40M | 22.20M | 413.00K | 3.08M | 13.02M | -18.00K | 36.77M | -3.38M | - | 4.32M | 6.56M | 7.94M | 86.24M |
| Capital Expenditure | -701.24K | -923.96K | -296.93K | -73.08K | -4.68M | -903.94K | -2.00K | -25.00K | -58.00K | -223.00K | -216.00K | -91.00K | -69.00K | -84.00K | -33.00K | -25.00K | -60.00K |
| Free Cash Flow | -25.38M | -25.44M | -22.36M | -19.94M | -28.00M | -28.26M | -767.00K | -811.00K | -4.91M | -5.53M | -6.67M | -7.34M | -9.42M | -11.63M | -8.57M | -8.85M | -13.11M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Nov 2014 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | 73.7% | 88.2% | 82.4% | 80.8% | 514.6% | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Margin % | -2,958.9% | -2,057.5% | -2,300.1% | -1,601.5% | -16,304.8% | -3,053.2% | - | 782.8% | - | - | - | - | - | - | - | - | - | - |
| Net Margin % | -2,722.0% | -1,769.0% | -1,747.3% | -2,082.8% | -15,345.1% | -3,234.1% | - | -787.9% | - | - | - | - | - | - | - | - | - | - |
| ROE % | -88.6% | -163.1% | -198.9% | -203.7% | -176.8% | - | -3,820.5% | 1,439.1% | -569.8% | -76.0% | -545.9% | -23.0% | -37.7% | -78.7% | -180.7% | -238.6% | -324.2% | -16.9% |
| ROCE % | - | -117.1% | -143.6% | -87.4% | -86.6% | - | -147.7% | 257.7% | -372.7% | 50.2% | -544.7% | -22.4% | -36.5% | -76.8% | -177.8% | -217.0% | -325.5% | -18.9% |
Shareholding Pattern
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for MBOT
MBOT Stock Falls As Investors Ponder Impact Of Geopolitical Tensions On Israel-Founded Company - Stocktwits
<a href="https://news.google.com/rss/articles/CBMi2wFBVV95cUxNaFBsUERiR0JvTUZIR29TWkxtX1pGd2c3cTMzX0cta2cxQ2J3WTItNTFSbVdyZUlDd3pqeFc1LUJsRU9lbXdzUWxLcEV0NGZwYWF1YU5KQjNDaUFjdFk4UmNuSGpJeGF1ZmhpcWtPWVhfUVQ0VWhMd3JkbjMxRTloTGZPZUItOW5VWTc5VV…
Microbot Medical Inc. Revenue Breakdown – NASDAQ:MBOT - TradingView
<a href="https://news.google.com/rss/articles/CBMid0FVX3lxTE9VQ0xSZHJ3aDhnbTFPT0lOT3BUVUJ3WjZyM3hsY2lBeFpNNTNhUWl6c2FQajJERVZCcW91SkxiVVpVaGlTNlc4endOOXVEbzJjVFBHaFdUR0VoMjR1WHVuUWNJRTdmdXpPWFplLVhmLUtxYXZWcXBF?oc=5" target="_blank">Microbo…
Microbot Medical taps Sanmina to scale LIBERTY robot production - Stock Titan
<a href="https://news.google.com/rss/articles/CBMivwFBVV95cUxQbDlvUUFrb3d6SnlGYVJzSlRCbU1WaU9RZkx0MS1Pd3RLOHJrXzdXQktTMmtpZlVudnl4ZzhoS0NXLWlXajVTZHZyZ0RvRDFqdWExV0lnRk1JZ0VQRU80OWs4NUtBXzRuZXNOMHVQTEc1WE9WMTl6NzZsT01rX2thcTdaUHIxaHVBUUZ3Vj…
After Plunging 22.6% in 4 Weeks, Here's Why the Trend Might Reverse for Microbot Medical (MBOT) - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMijwFBVV95cUxOS1RhOHQ3Y3FYY28zeUQyalFtSnVYZ0FzUnA1ZjhfNnpWeDliRk9WQnFwWFpLQllLYlN2U1ZDR3J1dXdtVF9LQWtNV3hoRGg2OWt5Z2NfNTB4N3VGQzYyeThtNGFSNVlpSUNHYlcwV1hQMUE0V0tjc1BpczNvT2MyZk0xaFhOdG9yOUxLMW…
MBOT|Microbot Medical Inc|Price:1.760|Chg%:+0.040 - TradingKey
<a href="https://news.google.com/rss/articles/CBMibkFVX3lxTE1Db1AtRU5sQ3ZRbFE4M3dneDNKSUxrd004Y1FuVnRNcDEwQXRQV3pVY0NjTWE4b0daUkRTQnFUQzUzSk8zMmJYMTFTUW1kempXMDkyV3hYcWZDLWpGRjRGVzlDMmFzd0pHaE0taWlR?oc=5" target="_blank">MBOT|Microbot Medic…
We're Hopeful That Microbot Medical (NASDAQ:MBOT) Will Use Its Cash Wisely - simplywall.st
<a href="https://news.google.com/rss/articles/CBMi0wFBVV95cUxNY2lqUUM5UDNGS01rbVNzUm43bllWb2pBRWpRbVFEeEQ0M3lwcEZWY0U5emJ3aTRDamd0bTBwSE1SS1lQQjFwcVc5eWNsRHRtQVoySEptejdQaWJrWngzdnl1ZDNLaXhWV3JWdjJUcDZiRjY1VkdJQWdueVgxRE9hQ2p3aENnVjVad2Z2a0…
MBOT — Frequently Asked Questions
What is the current share price of MBOT?
As of 2026-08-05 17:25 PDT, MBOT trades at $1.85 on NASDAQ/NYSE. Its 52-week range is $1.62 to $4.50.
What is the P/E ratio of MBOT?
MBOT trades at a trailing price-to-earnings (P/E) ratio of -6.38.
What is the return on equity (ROE) of MBOT?
MBOT has a return on equity (ROE) of -16.95%. Its return on capital employed (ROCE) is -18.87%.
Is MBOT a good stock to buy?
This page provides a data-driven analysis of MBOT, including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.